In the complex world of healthcare, where the line between patient care and profit can be blurred, the role of pharmacy benefit managers (PBMs) has come under intense scrutiny. These middlemen, who negotiate drug prices and coverage, have been accused of driving up costs and stifling competition. But what makes this issue particularly fascinating is the extent to which PBMs, along with other 'Big Medicine' conglomerates, have captured the healthcare system, leaving Americans with middling care and the highest medical costs in the world. From my perspective, the situation is not just about high drug prices; it's about the structural power of these entities and the systemic risks they pose to the healthcare system. In this article, I'll delve into the intricacies of the PBM problem, explore the broader implications of 'Big Medicine', and discuss why breaking up these conglomerates might be the key to a healthier, more affordable healthcare system. But first, let's understand the PBM problem in microcosm.
